Posted by Michael Wonder on 16 Apr 2021
ICER publishes final evidence report and policy recommendations on therapies for lupus nephritis
16 April 2021 - For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both treatments for patients and families beyond health improvement.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of belimumab (Benlysta, GlaxoSmithKline) and voclosporin (Lupkynis, Aurinia) for the treatment of lupus nephritis.
